BioGend Business Summary

BioGend Therapeutics (6733.TWO) is a commercial-stage regenerative medicine company specializing in orthopedic tissue engineering and advanced biomaterials. The company generates revenue through the direct sale of proprietary surgical kits and biologics, supplemented by milestone and royalty payments from international licensing agreements. Its primary business segments are centered on the "RevoCart" autologous cartilage repair system—the world’s first "one-step" cartilage regeneration solution—and the "OIF" (Osteo-Inductive Factor) platform for bone graft substitution and spinal fusion. As of 2026, BioGend has established a robust position in the Asia-Pacific market by offering a cost-effective, single-procedure alternative to traditional multi-stage cell therapies. Key direct competitors include Vericel Corporation, Smith & Nephew, and Medtronic’s biologics division; BioGend distinguishes itself through its simplified surgical workflow and reduced hospitalization requirements compared to traditional autologous chondrocyte implantation. The company was founded in 2016 as a strategic spin-off from Taiwan’s Industrial Technology Research Institute (ITRI) and is currently led by Chairman and CEO Dr. Chen-Yuan (Jerry) Chen, a physician-scientist with extensive experience in orthobiologic R&D and clinical regulatory affairs. The executive team includes veterans from global pharmaceutical firms and specialized researchers from the ITRI ecosystem, ensuring a high degree of technical synergy between product development and commercial scaling. BioGend is a core portfolio company of Center Laboratories (Center Lab), one of Taiwan’s most prominent healthcare investment groups, which provides significant financial backing and strategic guidance. The board of directors features a mix of industry experts and venture capitalists, reflecting the company’s dual focus on clinical innovation and aggressive international commercialization across China, the ASEAN region, and Western markets.